Professor
Director, Center for TB Research
MD, 82' University of Massachusetts Medical School
School of Medicine
Medicine
Infectious Diseases
International Health, Epidemiology
Center for Tuberculosis Research
Richard E. Chaisson, M.D., is Professor of Medicine, Epidemiology and International Health and Director of the Johns Hopkins University Center for Tuberculosis Research. From 1988-1998 he was Director of the Johns Hopkins AIDS Service, and co-founded the Johns Hopkins HIV Clinic cohort, an observational study that has been the source of more than 130 scientific publications on the outcomes of HIV disease and its treatment. In 1998 he founded the Center for Tuberculosis Research, a multidisciplinary research and training center with more than $100 million in grants for the study of TB from bench to bedside. Dr. Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology and control, prevention, clinical trials, and public health interventions. He is currently principal investigator of 11 research grants, and is principal investigator of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB. He has published over 350 scientific papers and book chapters.
Tuberculosis, HIV, Infectious Diseases
World Lung Health Award, American Thoracic Society, 2006
Research Projects
A Case-Control Study Investigating the Intersection Between Tobacco Use, Tuberculosis and HIV-infection
The overall objective of this proposal is to investigate the association between tobacco use and tuberculosis in HIV-infected males in Johannesburg, South Africa where rates of all three epidemics are extremely high. We will conduct a case-control study restricting all participants to HIV...
A Randomized Trial of Novel TB Preventive Regimens for HIV-Infected Adults in Soweto, South Africa
This is a four-arm study of alternative preventive therapy regimens for latent TB in HIV-infected adults. The study will provide critically important information on the most effective therapies to prevent HIV-related TB, and will assess the potency of short-course regimens containing rifamycins,...
CDC Tuberculosis Trials Consortium
The TBTC is a collaboration of researchers from the CDC, domestic and international public health departments, academic medical centers, and selected Veterans Administration medical centers whose mission is to conduct programmatically relevant research concerning the diagnosis, clinical...
Clinical Research in Tuberculosis
Dr. Chaisson proposed to provide support for patient oriented research on tuberculosis control in developing countries, mentoring of junior faculty and fellows in clinical research, and leadership of the Johns Hopkins Center for TB Research, which was founded at the time of the original award....
DOT-HAART For HIV-Infected South African Adults
The primary objective of this study is to evaluate the effectiveness and feasibility of directly observed therapy (DOT) using patient-nominated peer supervisors as a strategy to improve adherence to highly active antiretroviral therapy (HAART) in HIV-infected adults in South Africa. This country...
Effect of community-wide isoniazid preventive therapy on tuberculosis among South African gold miners. A project of Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE)
Thibela means prevent in Sotho, the predominant language of the gold miners of South Africa. Thus, the study''''s name, Thibela TB, describes the study''''s purpose: to measure the maximum possible benefit of community-wide isoniazid preventive therapy (IPT) on TB incidence and prevalence at a...
Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment, TBTC Study 28
CDC funded multicenter study. Prospective, randomized Phase II clinical study of moxifloxacin-based regimen for intensive phase of active TB treatment. Collaborating institution: Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Impact of TB Preventive Therapy for HIV/TB Co-infected Patients with Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial. A project of Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE)
The THRio study is designed to determine whether the routine detection and treatment of TB infection found in HIV infected patients in HIV clinics in Rio de Janeiro, Brazil, reduces TB incidence in the clinic population receiving HIV care. Involving an estimated 15,000 clinic patients, the...
Longitudinal Study of HIV-Associated Lung Infections in Soweto
In sub-Saharan Africa rates of tuberculosis (TB) and HIV infection are extremely high. TB is the leading cause of death in HIV-infected adults and often is the initial clinical manifestation. TB in HIV-infected patients carries a high risk of death which occurs predominantly in the first days to...
Novel TB Prevention Regimens for HIV-Infected Adults
Tuberculosis (TB) continues to kill approximately 2 million people per year, and is a major cause of HLV-related morbidity and mortality in developing countries. In addition, TB appears to cause a more rapid progression of HIV disease even when it is successfully treated, as active TB causes...
Peer and Family-Based Social Support For HIV Treatment Adherence in South Africa
The goal of this study is to understand the role of family or peer support as a tool for improving adherence to antiretroviral therapy in an HIV positive population in the Western Cape Province of South Africa. Data will be collected from a clinical trial evaluating the impact of community-based...
South African Tb/AIDS Training
The goal of the South African TB-AIDS Training (SATBAT) program is to expand the ability of South African investigators to conduct state-of-the-art operational, health services and clinical research relevant to the twin epidemics of TB/AIDS. The President’s Emergency Plan for AIDS (PEPFAR) and...
TBTC Tuberculosis Trial Consortium
The TBTC is a collaboration of researchers from the CDC, domestic and international public health departments, academic medical centers, and selected Veterans Administration medical centers whose mission is to conduct programmatically relevant research concerning the diagnosis, clinical...
ZAMSTAR: Zambia and South Africa tuberculosis and AIDS reduction study. A study of the Consortium To Respond Effectively To the AIDS/TB Epidemic (CREATE).
A total of 24 communities in Zambia and Cape Town communities in South Africa, with 25,000 to 50,000 people in each community will take part in the ZAMSTAR study. This is a community-randomized trial of two interventions with a factorial design. All communities will experience strengthened DOTS...
Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-8. -
Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, Marais E, McIntyre J, Chaisson RE, Hale M. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007;21:2043-50. -
Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model.PLoS Med. 2007 Dec 18;4(12):e344. -
Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, Chaisson RE, Churchyard GJ, Grant AD. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS. 2008 Jan 2;22(1):67-74. -
Pemba L, Charalambous S, von Gottberg A, Magadla B, Moloi V, Seabi O, Wasas A, Klugman KP, Chaisson RE, Fielding K, Churchyard GJ, Grant AD. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus -
pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect. 2008;56:171-8. -
Pope DS, Deluca AN, Kali P, Hausler H, Sheard C, Hoosain E, Chaudhary MA, Celentano DD, Chaisson RE. A Cluster-Randomized Trial of Provider-Initiated (Opt-Out) HIV Counseling and Testing of Tuberculosis Patients in South Africa. J Acquir Immune Defic Syndr. 2008;48:190-195. PMCID: 2632747 -
Saraceni V, King BS, Cavalcante SC, Golub JE, Lauria LM, Moulton LH, Chaisson RE, Durovni B. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2008;12:769-72. -
Charalambous S, Grant AD, Moloi V, Warren R, Day JH, van Helden P, Hayes RJ, Fielding KL, De Cock KM, Chaisson RE, Churchyard GJ. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis. 2008;12:942-8. -
Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A. 2008;105(32):11293-8. PMCID: 2516234 -
Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008; 52(11):4037-42. PMCID: 2573112 -
Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS ONE. 2008;3(9):e3132. PMCID: 2518952 -
Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008;208:2117-25. PMCID: 2659649 -
Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008; 47(11):1479-85. PMCID: 2670447 -
Pacheco AG, Saraceni V, Tuboi SH, Moulton LH, Chaisson RE, Cavalcante SC, Durovni B, Faulhaber JC, Golub JE, King B, Schechter M, Harrison LH. Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil. Am J Epidemiol. 2008; 168(11):1326-32. PMCID: 2638543 -
Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE. Long-Term Effectiveness of Diagnosing and Treating Latent Tuberculosis Infection in a Cohort of HIV-Infected and At-Risk Injection Drug Users. J Acquir Immune Defic Syndr. 2008; 49(5):532-7. PMCID: 2637943 -
Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2008;22:2527-2533. PMCID: 2603140 -
Dowdy DW, Lourenco MC, Cavalcante SC, Saracen V, King B, Golub JE, Bishai D, Durovni B, Chaisson RE, Dorman SE. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 2008; 3(12): e4057. PMCID: 2614861 -
Aguiar F, Vieira MA, Staviack A, Buarque C, Marsico A, Fonseca L, Chaisson RE, Kristski A, Werneck G, Mello F. Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis. 2009; 13:54-61. -
Conde MB, Efron A, Loredo C, De Souza GRM, Graça NP, Cezar MC, Ram M, Chaudhary MA, BishaiWR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial therapy of tuberculosis: A randomized, controlled, phase 2 Trial. Lancet 2009,373:1183-9. -
Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G. Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. J Acquir Immune Defic Syndr. 2009 2009;51:65-71. PMCID: 2674125 -
Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, Chaisson RE, Conde MB, Boechat N, Dorman SE. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis. 2009;9:23. PMCID: 2651889 -
Cailleaux-Cezar M, de A Melo D, Xavier GM, de Salles CL, de Mello FC, Ruffino-Netto A, Golub JE, Efron A, Chaisson RE, Conde MB. Tuberculosis incidence among contacts of active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009; 13:190-5. -
Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-6. -
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE. Substitution of Moxifloxacin for Isoniazid During Intensive Phase Treatment of Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2009;180:273-80. -
Dowdy DW, Chaisson RE. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull WHO 2009; 87:296–304. PMCID: PMC2672581. -
Hoffmann CJ, Charalambous S, Fielding KL, Innes C, Chaisson RE, Grant AD, Churchyard GJ. HIV suppression with stavudine 30 mg versus 40mg in adults over 60 kg on antiretroviral therapy in South Africa. AIDS. 2009;23:1784-6. -
Martinson NA, Moultrie H, van Niekerk R, Barry G, Coovadia A, Cotton M, Violari A, Gray GE, Chaisson RE, McIntyre JA, Meyers T. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009;13:862-7. -
Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, Wong M, Luke B, Martin DJ, Chaisson RE, Dorman SE, Martinson NA. Diagnostic Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in Hospitalized Patients in a High HIV Prevalence Setting. J Acquir Immune Defic Syndr. 2009;52:145-51. -
Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, Fielding KL, Churchyard GJ, Morris L, Grant AD. Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa. Clin Infect Dis. 2009;49:1928-35. -
Cavalcante SC, Durovni B, Barnes GL, Souza FB, Silva RF, Barroso PF, Mohan CI, Miller A, Golub JE, Chaisson RE. Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2010;14:203-9. -
Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, Golub JE. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med. 2010 Mar 2. [Epub ahead of print]
|
|
